ArticleCancer immunology, immunotherapy : CII2020

Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity.

Airi Harui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.